906 reports of this reaction
1.9% of all MIDAZOLAM HYDROCHLORIDE reports
#8 most reported adverse reaction
CARDIAC ARREST is the #8 most commonly reported adverse reaction for MIDAZOLAM HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 906 FDA adverse event reports linking MIDAZOLAM HYDROCHLORIDE to CARDIAC ARREST. This represents approximately 1.9% of all 46,685 adverse event reports for this drug.
Patients taking MIDAZOLAM HYDROCHLORIDE who experience cardiac arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC ARREST is a less commonly reported adverse event for MIDAZOLAM HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to cardiac arrest, the following adverse reactions have been reported for MIDAZOLAM HYDROCHLORIDE:
The following drugs have also been linked to cardiac arrest in FDA adverse event reports:
CARDIAC ARREST has been reported as an adverse event in 906 FDA reports for MIDAZOLAM HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC ARREST accounts for approximately 1.9% of all adverse event reports for MIDAZOLAM HYDROCHLORIDE, making it a notable side effect.
If you experience cardiac arrest while taking MIDAZOLAM HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.